Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients with ...
Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients with newly diagnosed prostate cancer considering first-line treatment, ...
Daniel Spratt, MD, member of Case CCC's Developmental Therapeutics Program, conducted a retrospective cohort study assessing the associations between the Decipher Genomic Classifier (Decipher GC), a ...
Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019) Men with potentially lethal PC (metastatic, localized with a Gleason score of ≥8, persistent prostate-specific antigen ...
A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...
The study, which was led by Ming-Yeh Yang and Ching-Yuan Huang of Tzu-Chi University, aimed to develop a rapid, sensitive and feasible method to determine 25(OH)D3 levels in blood for clinical ...
For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk classification or treatment decisions, according to a review published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results